Prosthetic heart valves: Objective Performance Criteria versus randomized clinical trial

Area of Science:

• Medical Devices
• Clinical Trials
• Cardiovascular Research

Background:

• The U.S. Food and Drug Administration (FDA) currently utilizes Objective Performance Criteria (OPC) for evaluating prosthetic heart valve clinical performance.
• OPC, functioning as historical controls, have proven adequate and potentially optimal for assessing heart valves due to their simple mechanism and well-understood complications.

Discussion:

• Randomized clinical trials (RCTs) have not been mandated by the FDA for prosthetic heart valve approval, as OPC-based studies have demonstrated efficacy.
• Post-approval, RCTs are sometimes conducted for comparative purposes; however, the Artificial Valve Endocarditis Reduction Trial (AVERT) highlighted potential inefficiencies.

Key Insights:

• The AVERT trial, designed to compare a novel Silzone sewing ring against a standard one, was prematurely terminated due to a high leak rate.
• Analysis indicated that a significantly smaller OPC-based study (800 patient-years) would have sufficed to identify the Silzone valve's leak complication.

Outlook:

• This case suggests that OPC methodology may be more efficient than large-scale RCTs for detecting specific complications in prosthetic heart valves.
• Future regulatory strategies could benefit from refining OPC to ensure robust detection of critical adverse events, optimizing resource allocation in clinical research.